London, UK, 24 May 2021: Kuano Ltd is pleased to announce the appointment of Dr Andy Mulvaney to its Board as a Non-Executive Director. Andy is a seasoned industry executive and, in addition to hands-on experience of contributing to the formation and development of a highly successful biotech, Summit Therapeutics, Inc. (NASDAQ: SMMT), brings broad corporate, business and operational development experience to Kuano.
Dr Vid Stojevic, CEO at Kuano, said:
“We are delighted to have Andy join our Board and will benefit greatly from his strategic input and business expertise.”
Dr Andy Mulvaney said:
“I am pleased to be joining Kuano at this pivotal stage in their development. Their unique combination of expertise and technology in quantum chemistry, AI/ML and drug discovery positions them ideally to exploit opportunities for first-in-class inhibitors for intractable enzyme targets, as well as to tackle challenges associated with inhibitors of validated enzyme targets with established $billion markets. I look forward to working with the Kuano management team and Board to help Kuano deliver on the promise of its ground-breaking technology.”